XML 34 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
Restructuring Costs
 12 Months Ended
Dec. 31, 2016
Restructuring and Related Activities [Abstract]  
Restructuring Costs
12. Restructuring Costs

In June 2016, the Company halted investment in PNT2258 and the DNAi platform and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the year ended December 31, 2016:

 

     Contract
Termination		      Employee
Termination		      Asset
Impairment		      Total  
     (in thousands)  

Accrual balance at December 31, 2015

    $ —        $ —        $ —        $ —    

Restructuring costs charged to research and development expense

      2,249        —          —          2,249  

Restructuring costs charged to general and administrative expense

      5        332        130        467  

Non-cash charges

      (681 )       —          (130 )       (811 ) 

Cash payments

      (909 )       (233 )       —          (1,142 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Accrual balance at December 31, 2016

    $ 664      $ 99      $ —        $ 763  
  

 

 

     

 

 

     

 

 

     

 

 

  

Total restructuring costs recorded during the year ended December 31, 2016 were $2.7 million. The accrual balance is currently expected to be paid by the end of 2017.

There were no restructuring activities during the year ended December 31, 2015.